Valuation: C4 Therapeutics, Inc.

Market Cap 433M 379M 350M 323M 609M 41.63B 620M 4.18B 1.64B 20.39B 1.63B 1.59B 70.19B P/E 2026 *
-4.2x
P/E 2027 * -3.89x
Enterprise Value 433M 379M 350M 323M 609M 41.63B 620M 4.18B 1.64B 20.39B 1.63B 1.59B 70.19B EV / Sales 2026 *
22.9x
EV / Sales 2027 * 22.6x
Free-Float
99.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day-2.68%
1 week-12.64%
Current month-18.63%
1 month-0.52%
3 months+37.68%
6 months+63.09%
Current year+98.95%
1 week 3.72
Extreme 3.725
4.4
1 month 3.6
Extreme 3.605
5.17
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
51.21
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 2020-10-01
Director of Finance/CFO 49 2023-09-17
Chief Tech/Sci/R&D Officer 56 2024-10-27
Director TitleAgeSince
Director/Board Member 74 2015-11-30
Director/Board Member 55 2020-09-13
Director/Board Member 55 2022-03-15
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Founder

2,650 0.0024%
06-30Free

Director

3,341 0.0030%
06-23Free

Chairman

62,000 0.0561%
Change 5-day change 1-year change 3-year change Capi.($)
-2.68%-12.64%+59.66%+13.43% 433M
-1.05%+1.39%+3.15%+6.98% 50.61B
+0.44%-2.97%+381.63%+593.17% 39.11B
+0.30%-0.30%+29.65%-6.10% 34.64B
+0.85%-0.87%+21.47%+56.00% 33.79B
-1.31%-1.76%+1.59%+27.01% 26.89B
+0.37%-0.08% - - 16.47B
+1.56%-1.56%+67.86%+121.11% 15.14B
-0.72%+0.12%+14.69%+16.95% 13.85B
+1.41%-0.14%+12.69%-31.58% 12.72B
Average -0.07%-1.92%+65.82%+88.55% 24.37B
Weighted average by Cap. +0.04%-1.15%+80.54%+121.62%

Financials

2026 *2027 *
Net sales 18.92M 16.54M 15.29M 14.13M 26.6M 1.82B 27.08M 182M 71.53M 890M 71.09M 69.52M 3.06B 19.14M 16.73M 15.46M 14.29M 26.9M 1.84B 27.39M 184M 72.35M 900M 71.89M 70.31M 3.1B
Net income -119M -104M -96.28M -88.95M -168M -11.45B -171M -1.15B -450M -5.61B -448M -438M -19.3B -151M -132M -122M -112M -212M -14.48B -216M -1.45B -570M -7.09B -566M -554M -24.41B
Net Debt - -
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
26-07-14 US$3.812 -2.76% 2,416,329
26-07-13 US$3.920 -3.45% 3,013,353
26-07-10 US$4.060 -5.36% 2,583,449
26-07-09 US$4.290 +2.39% 2,536,283
26-07-08 US$4.190 -3.68% 6,712,598
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.920USD
Average target price
13.33USD
Spread / Average Target
+240.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CCCC Stock